Showing results (181-190 of 192) with videos related to
Sort By:
Pageof 20
Journal of the National Comprehensive Cancer Network : JNCCN|August 11, 2012
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelinesMargaret von Mehren, Robert S Benjamin, Marilyn M Bui, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 14, 2014
Gastrointestinal stromal tumors, version 2.2014Margaret von Mehren, R Lor Randall, Robert S Benjamin, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2016
Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in OncologyMargaret von Mehren, R Lor Randall, Robert S Benjamin, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2018
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyMargaret von Mehren, R Lor Randall, Robert S Benjamin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2019
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008Uta Dirksen, Bernadette Brennan, Marie-Cécile Le Deley, et al.The Lancet. Oncology|July 24, 2020
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trialAaron R Weiss, Yen-Lin Chen, Thomas J Scharschmidt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2015
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan S Bielack, Sigbjørn Smeland, Jeremy S Whelan, et al.European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, et al.The Lancet. Oncology|August 30, 2016
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, et al.Science (New York, N.Y.)|January 19, 2023
Heritable defects in telomere and mitotic function selectively predispose to sarcomasMandy L Ballinger, Swetansu Pattnaik, Piyushkumar A Mundra, et al.Pageof 20